Sign in

NMTC on Nasdaq

NEUROONE MEDICAL TECHNOLOGIES Corp

NEUROONE MEDICAL TECHNOLOGIES Corp is an American surgical and medical instruments and apparatus company.1 It is headquartered in Eden Prairie, Minnesota.1 Its shares trade on Nasdaq under the symbol NMTC.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with InspireMD, Inc., Medinotec Inc. or WORK Medical Technology Group LTD, or pick any stock.

  • TickerNMTC on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersEden Prairie, Minnesota1
  • Incorporated inDE2
  • Business address7599 Anagram Dr, Eden Prairie, Mn 553442
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

(i) diagnostic, ablation and deep brain stimulation technology for brain related conditions such as epilepsy and Parkinson’s disease;3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

56.5%Gross margin4
-46.5%Operating margin4
-39.6%Net margin4
163.5%Revenue growth, 20254
-51.0%Return on equity4
-$2.9MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue24¢$4.0M
  • Research and development31¢$5.0M
  • Selling, general and admin45¢$7.4M

Out of $9.1M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$9.1M in 2025+5007% since 2021
0$2.5M$5.0M$7.5M$10.0M2021: $178.1K$178.1K20212022: $171.2K$171.2K2022−4%2023: $2.0M$2.0M2023+1041%2024: $3.5M$3.5M2024+77%2025: $9.1M$9.1M2025+163%
Gross profit5674$5.1M in 2025
-$2.0M0$2.0M$4.0M$6.0M2021: -$97.7K-$97.7K20212022: -$70.8K-$70.8K2022−28%2023: $456.5K$456.5K20232024: $1.1M$1.1M2024+137%2025: $5.1M$5.1M2025+376%
Operating income895674-$4.2M in 2025−27% since 2019
-$15.0M-$10.0M-$5.0M02019: -$5.8M-$5.8M20192020: -$4.9M-$4.9M2020−16%2021: -$10.2M-$10.2M2021+108%2022: -$10.0M-$10.0M2022−2%2023: -$12.0M-$12.0M2023+19%2024: -$11.9M-$11.9M2024−1%2025: -$4.2M-$4.2M2025−64%
Net income1095674-$3.6M in 2025−22% since 2019
-$15.0M-$10.0M-$5.0M02019: -$4.6M-$4.6M20192020: -$13.6M-$13.6M2020+194%2021: -$9.9M-$9.9M2021−27%2022: -$10.0M-$10.0M2022+1%2023: -$11.9M-$11.9M2023+19%2024: -$12.3M-$12.3M2024+4%2025: -$3.6M-$3.6M2025−71%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-09-302024-09-30
Product revenue$9.1M$3.5M
Cost of product revenue$4.0M$2.4M
Product gross profit$5.1M$1.1M
Collaborations revenue$3.0M
Selling, general and administrative$7.4M$7.9M
Research and development$5.0M$5.1M
Total operating expenses$12.4M$13.0M
Loss from operations-$4.2M-$11.9M
Fair value change in warrant liability$784.7K-$327.1K
Financing costs-$334.1K-$229.0K
Other income, net$170.5K$125.2K
Loss before income taxes-$3.6M-$12.3M
Net loss-$3.6M-$12.3M
Basic (in Dollars per share)-$0.09-$0.46
Diluted (in Dollars per share)-$0.09-$0.46
Basic (in Shares)40.2M shares26.8M shares
Diluted (in Shares)40.2M shares26.8M shares

Compare NEUROONE MEDICAL TECHNOLOGIES Corp with another company

Corporate structure

NEUROONE MEDICAL TECHNOLOGIES Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NEUROONE MEDICAL TECHNOLOGIES Corp

  • Brian Pratt Filed SCHEDULE 13G/A on NEUROONE MEDICAL TECHNOLOGIES Corp, latest Jul 14, 2026 (2 filings since Apr 21, 2026)
  • Sio Capital Management, LLC Filed SCHEDULE 13G/A on NEUROONE MEDICAL TECHNOLOGIES Corp, latest Nov 12, 2025 (2 filings since Aug 13, 2025)
  • Bleichroeder LP Filed SCHEDULE 13G on NEUROONE MEDICAL TECHNOLOGIES Corp, latest Aug 14, 2025
  • Laurence W. Lytton Filed SCHEDULE 13G/A on NEUROONE MEDICAL TECHNOLOGIES Corp, latest May 15, 2025 (3 filings since Jan 11, 2024)
  • AWM Investment Company, Inc. Filed SCHEDULE 13G/A on NEUROONE MEDICAL TECHNOLOGIES Corp, latest May 9, 2025 (2 filings since Nov 14, 2024)
  • MANCHESTER MANAGEMENT CO LLC Filed SCHEDULE 13G/A on NEUROONE MEDICAL TECHNOLOGIES Corp, latest Feb 14, 2025 (2 filings since Aug 2, 2023)
  • MERCHANT ADVENTURE FUND, L.P. Filed SCHEDULE 13G/A on NEUROONE MEDICAL TECHNOLOGIES Corp, latest Feb 4, 2025 (2 filings since Jan 29, 2024)
  • Nantahala Capital Management, LLC Filed SCHEDULE 13G/A on NEUROONE MEDICAL TECHNOLOGIES Corp, latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • NEUROONE MEDICAL TECHNOLOGIES Corp Eden Prairie, Minnesota

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NEUROONE MEDICAL TECHNOLOGIES Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Furniture and fixtures$1.1M4 Sep 30, 2025$976.3K4 Sep 30, 2024+8.4%
Property and equipment, before depreciation$1.1M4 Sep 30, 2025$976.3K4 Sep 30, 2024+8.4%
Accumulated depreciation$798.8K4 Sep 30, 2025$559.5K4 Sep 30, 2024+42.8%
Property and equipment, net$259.2K4 Sep 30, 2025$416.8K4 Sep 30, 2024−37.8%
Operating-lease assets (leased space)$255.2K4 Sep 30, 2025$254.9K4 Sep 30, 2024+0.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.6M4 Sep 30, 2025$1.5M4 Sep 30, 2024+350.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$44.9K4 Sep 30, 2025$67.3K4 Sep 30, 2024−33.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$2.2M4 Sep 30, 2025$2.6M4 Sep 30, 2024−15.5%
Work in process$10.0K4 Sep 30, 2025$04 Sep 30, 2024
Finished goods$1.2M4 Sep 30, 2025$1.6M4 Sep 30, 2024−21.7%

Properties, in its own words

We currently lease office space in Eden Prairie, Minnesota and Los Gatos, California to accommodate our finance and administrative functions as well as laboratory space accommodating our research and development operations. We believe that our existing facilities are adequate for our immediate needs and can accommodate our anticipated growth. We believe that, should it be needed, additional space can be leased to accommodate any future growth.

Item 2 of the 10-K filed Dec 17, 2025.3

Leadership

Who has led NEUROONE MEDICAL TECHNOLOGIES Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lecia Walker2013
  2. Amer Samad2014–2017
  3. David A. Rosa2017–now

President

  1. David A. Rosa2019–now

Chief financial officer

  1. Lecia Walker2013
  2. Ronald W. McClurg2021–2026
  3. Christopher Volker2026–now

Chief operating officer

  1. Christopher Volker2023–now
201520202025
Board members and other officers (16)

Former names

  • Original Source Entertainment, Inc.Oct 4, 2010 to May 22, 20172

Timeline

  1. Oct 5, 20268-K Results of operations; Other events34
  2. Aug 27, 20268-K Other events35
  3. Aug 13, 20268-K Results of operations36
  4. Jun 12, 20268-K Other events37
  5. May 22, 20268-K Earlier financial statements no longer reliable; Regulation FD disclosure38
  6. May 12, 20268-K Results of operations39
  7. May 4, 20268-K Other events40
  8. Apr 30, 20268-K Executive or director change41
  9. Apr 14, 20268-K Bylaws or fiscal year changed42
  10. Apr 3, 20268-K Executive or director change; Shareholder vote43
  11. Feb 25, 20268-K Other events44
  12. Feb 17, 20268-K Results of operations45
  13. Jul 24, 2017New chief executive David A. Rosa becomes CEO14
  14. Apr 30, 2014New chief executive Amer Samad becomes CEO15
  15. May 2, 2013New chief executive Lecia Walker becomes CEO16

Calendar

When it reported results

  1. Oct 5, 2026Reported quarterly or annual results34
  2. Aug 13, 2026Reported quarterly or annual results36
  3. May 12, 2026Reported quarterly or annual results39
  4. Feb 17, 2026Reported quarterly or annual results45
  5. Dec 17, 2025Reported quarterly or annual results46
  6. Oct 6, 2025Reported quarterly or annual results47
  7. Aug 14, 2025Reported quarterly or annual results48
  8. May 13, 2025Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

336 filings to the SEC since October 2021: 7 annual reports, 16 quarterly reports, 68 major events, 173 insider forms, 16 large holders, 1 private raises, 55 other. The latest 20:

  1. Oct 5, 20268-K CURRENT REPORT EDGAR
  2. Sep 8, 20264 PRIMARY DOCUMENT EDGAR
  3. Aug 28, 20264 PRIMARY DOCUMENT EDGAR
  4. Aug 28, 20264 PRIMARY DOCUMENT EDGAR
  5. Aug 28, 20264 PRIMARY DOCUMENT EDGAR
  6. Aug 28, 20264 PRIMARY DOCUMENT EDGAR
  7. Aug 28, 20264 PRIMARY DOCUMENT EDGAR
  8. Aug 27, 20268-K CURRENT REPORT EDGAR
  9. Aug 13, 202610-Q QUARTERLY REPORT EDGAR
  10. Aug 13, 20268-K CURRENT REPORT EDGAR
  11. Jul 14, 20263 PRIMARY DOCUMENT EDGAR
  12. Jul 14, 2026SCHEDULE 13G/A EDGAR
  13. Jul 2, 20264 PRIMARY DOCUMENT EDGAR
  14. Jun 30, 2026144 EDGAR
  15. Jun 12, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  16. Jun 12, 20268-K CURRENT REPORT EDGAR
  17. Jun 12, 202610-Q/A AMENDMENT NO. 1 TO FORM 10-Q EDGAR
  18. May 29, 2026SD SPECIALIZED DISCLOSURE REPORT EDGAR
  19. May 29, 2026SD SPECIALIZED DISCLOSURE REPORT EDGAR
  20. May 22, 20268-K CURRENT REPORT EDGAR

The 336 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

31 open-market trades by officers, directors and large owners since October 2021: 10 buys and 21 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 27, 2026Wambeke David J.Chief Business OfficerBuy33,333$2.01$67.0KForm 4
Jun 30, 2026Christianson MarkMarket Development DirectorSale10,000$3.18$31.8KForm 4
Mar 30, 2026Christianson MarkMarket Development DirectorSale15,363$0.74$11.4KForm 4
Mar 13, 2026Christianson MarkMarket Development DirectorSale100$0.80$80Form 4
Mar 12, 2026Christianson MarkMarket Development DirectorSale817$0.80$654Form 4
Mar 11, 2026Christianson MarkMarket Development DirectorSale2,109$0.80$1.7KForm 4
Mar 10, 2026Christianson MarkMarket Development DirectorSale11,611$0.80$9.3KForm 4
Mar 1, 2026Wambeke David J.Chief Business OfficerBuy1,000,000$0.67$670.0KForm 4
Sep 5, 2025Christianson MarkMarket Development DirectorSale30,000$0.74$22.2KForm 4
Jun 4, 2025Christianson MarkMarket Development DirectorSale10,000$0.58$5.8KForm 4
May 22, 2025Christianson MarkMarket Development DirectorSale8,967$0.62$5.6KForm 4
May 21, 2025Christianson MarkMarket Development DirectorSale14$0.65$9Form 4
May 20, 2025Christianson MarkMarket Development DirectorSale3,013$0.66$2.0KForm 4
May 19, 2025Christianson MarkMarket Development DirectorSale8,006$0.67$5.4KForm 4
Apr 4, 2025McClurg Ronald W.Chief Financial OfficerBuy200,000$0.50$100.0KForm 4
Apr 4, 2025Rosa David ACEO & PresidentBuy100,000$0.50$50.0KForm 4
Jun 6, 2024Christianson MarkMarket Development DirectorSale2,189$0.88$1.9KForm 4
Jun 5, 2024Christianson MarkMarket Development DirectorSale25,800$0.88$22.7KForm 4
Dec 27, 2023Christianson MarkMarket Development DirectorSale31,445$1.46$45.9KForm 4
Dec 26, 2023Christianson MarkMarket Development DirectorSale6,848$1.35$9.2KForm 4

All 31 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Dave Rosa,61$535.4K$1.2M58
2025Christoper Volker,$294.9K$687.4K58
2025Ron McClurg,67$325.0K$523.8K58
2024Chief Executive Officer and President$521.9K$2.0M58
2024Chief Operating Officer$256.4K$712.1K58
2024Chief Financial Officer$316.8K$598.6K58

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 2, 2024Raised $276,043 in a private offering of securities Form D: 20 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bleichroeder LP666,666$2.0M0.4%New
Vanguard Capital Management LLC352,774$1.1M0.0%New
Bard Associates Inc305,428$928.5K0.2%New
Perkins Capital Management Inc244,656$743.8K0.6%New
Geode Capital Management, LLC93,555$284.4K0.0%New
Sio Capital Management, LLC82,767$251.6K0.0%New
Renaissance Technologies LLC70,861$215.4K0.0%New
Vanguard Fiduciary Trust Co49,018$149.0K0.0%New
Essex Investment Management Co LLC43,578$132.5K0.0%New
BlackRock, Inc.25,121$76.4K0.0%New
Northern Trust Corp21,398$65.0K0.0%New
Citadel Advisors LLC15,032$45.7K0.0%New
Susquehanna International Group, Llp13,520$41.1K0.0%New
Belpointe Asset Management LLC12,500$38.0K0.0%New
Legato Capital Management LLC10,273$31.2K0.0%New
UBS Group AG2,623$8.0K0.0%New
Morgan Stanley2,058$6.3K0.0%New
Northwestern Mutual Wealth Management Co361$1.1K0.0%New
Wells Fargo & Company/mn166$5050.0%New
Tower Research Capital LLC (TRC)112$3400.0%New
Barclays PLC76$2310.0%New
Osaic Holdings, Inc.58$1760.0%New
Cambridge Investment Research Advisors, Inc.56,998$1740.0%New
SBI Securities Co., Ltd.13$400.0%−7
Integrated Wealth Concepts LLC8$240.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How NEUROONE MEDICAL TECHNOLOGIES Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNEUROONE MEDICAL TECHNOLOGIES Corp1
  • CIK0001500198
  • Employer ID (EIN)27-08633543
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsSeptember 301
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address7599 Anagram Dr, Eden Prairie, MN 553441
  • Phone(952) 426-13831
  • Shares outstanding9,105,763 as of Aug 11, 202612
  • Public float$25.5M as of Mar 31, 20253
  • AuditorBaker Tilly US, LLP, Minneapolis, Minnesota PCAOB ID 23; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceOct 4, 20101
  • Filings653 in all: 4 (204), 8-K (149), 10-Q (46), 3 (23), UPLOAD (15), 10-K (14), 424B5 (14), CORRESP (14)1
    All 49 form types

    NT 10-Q (14), D (11), EFFECT (11), DEF 14A (9), 424B3 (8), S-1/A (8), S-8 (8), SC 13D (8), 10-K/A (7), SCHEDULE 13G/A (7), 144 (6), 8-K/A (6), NT 10-K (6), S-1 (6), SC 13D/A (5), SC 13G (5), ARS (4), D/A (4), PRE 14A (4), SC 13G/A (4), SCHEDULE 13G (4), SD (4), S-3 (3), 10-Q/A (2), DEFA14A (2), POS AM (2), S-3/A (2), 10-KT (1), 10-KT/A (1), 3/A (1), 4/A (1), 8-A12B (1), 8-A12G (1), CERT (1), CT ORDER (1), DEF 14C (1), DEL AM (1), PRE 14C (1), PRER14A (1), PRER14C (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Dec 17, 2025
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Mar 9, 2026
    Latest 8-K (8-K) Oct 5, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par value per shareNMTCNasdaq

From the cover page of the 10-K filed Dec 17, 2025 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks NEUROONE MEDICAL TECHNOLOGIES Corp names in Item 1A of its 10-K filed Dec 17, 2025: 56 risks under these headings, as written.3

  • Risks Related to Our Business
  • We have incurred significant operating losses since inception and cannot assure you that we will ever achieve or sustain profitability.
  • We have a limited operating history, making it difficult for you to evaluate our business and your investment.
  • Zimmer has exclusive global rights to distribute our Evo Cortical, Evo sEEG, and OneRF Ablation System in the brain. We are reliant on Zimmer to drive the commercialization and sales of these products. Zimmer’s failure to timely develop or commercialize these products, or to achieve certain milestones, would have a material adverse effect on our business and operating results.
  • Our ability to continue our operations requires that we raise additional capital and our operations could be curtailed if we are unable to obtain the additional funding as or when needed.
  • We may be adversely affected by the effects of inflation.
  • We will need to raise substantial additional funds in the future, and these funds may not be available on acceptable terms or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, scale back or cease some or all operations.
  • An inability to obtain a supply of components and raw material products could have a material adverse effect on our business, financial condition and results of operations.
  • We depend on a limited number of third-party suppliers for the components of our cortical strip, grid electrode and depth electrode technology, and the loss of any of these suppliers, or their inability to provide us with an adequate supply of materials, could harm our business.
  • Changes in the configuration of our technology under development may result in additional costs or delay.
  • We have four products which have each received 510(k) clearance from the FDA. If we are unable to successfully develop and receive regulatory clearance/approval for our other products under development, or if we experience significant delays in doing so, our business will be harmed.
  • Even if we obtain regulatory clearance and/or approval for all of our products, we will remain subject to extensive regulatory scrutiny and compliance obligations.
The other 45 risks
  • Potential complications from our technologies that are currently unknown may come to light.
  • post-operative hemorrhage, infection, brain inflammation, brain tissue necrosis, inability to accurately localize the epileptogenic focus (the area of the cerebral cortex responsible for causing epileptic seizures), neurologic deficit (abnormal function of a body area due to weaker function of the brain, spinal cord, muscles or nerves, such as abnormal reflexes, inability to speak and decreased sensation) and extra axial fluid collections (fluid that occurs in the brain after surgery).
  • temporary motor deficit, post-operative pain, skin burns hemorrhage, infection.
  • for Trigeminal nerve ablation, masseter weakness, paresthesias, diplopia, keratitis, corneal reflex impairment, anesthesia dolorosa, and vasomotor rhinorrhea.
  • Undetected errors or defects in our cortical strip/grid electrode system, depth electrode system, RF probes and RF generator ablation system technologies under development or future versions thereof could harm our reputation, decrease the market acceptance of cortical strip/grid electrode system, depth electrode system, RF probes and RF generator ablation system technology or expose us to product liability claims adversely affecting our financial condition and results of operations or liquidity.
  • We may not be successful in commercializing our technology.
  • The continuing development and commercialization of our products depends upon us maintaining strong relationships with academic and healthcare institutions and professionals.
  • Our success depends on our ability to continue to develop, commercialize and gain market acceptance for our products and technology.
  • Failure to secure or retain coverage or adequate reimbursement for our cortical strip, grid electrode and depth electrode technology or future versions thereof, including the implantation procedures, by third-party payors could adversely affect our business, financial condition and operating results.
  • Reimbursement by Medicare is highly regulated and subject to change.
  • If our competitors are better able to develop and market products for the diagnosis and treatment of epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that are safer, more effective, less costly, easier to use or otherwise more attractive than our cortical strip, grid electrode and depth electrode technology, our business will be adversely impacted.
  • The size and future growth in the market for our cortical strip, grid electrode and depth electrode technology and for other future products and technology under development have not been established with precision and may be smaller than we estimate, possibly materially. If our estimates and projections overestimate the size of these markets, our sales growth may be adversely affected.
  • We depend on our partnership with Mayo to license certain know how for the development and commercialization of our technology. Termination of this partnership would harm our business, and even if this partnership continues, it may not be successful.
  • We contract with third parties for the manufacture of our cortical strip, grid electrode and depth electrode technology and for our future products and technology under development, and expect to continue to do so for clinical trials and commercialization. Risks associated with the manufacturing of our products could reduce our gross margins and negatively affect our operating results.
  • Potential complications from our cortical strip, grid electrode and depth electrode technology that are currently unknown may come to light.
  • Undetected errors or defects in our cortical strip, grid electrode and depth electrode technology under development or future versions thereof could harm our reputation, decrease the market acceptance of our cortical strip, grid electrode and depth electrode technology or expose us to product liability claims adversely affecting our financial condition and results of operations or liquidity.
  • We depend on sophisticated information technology systems, and any breach or disruption affecting these systems could adversely affect our business, financial condition and operating results.
  • We have entered into, and may enter into additional collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues.
  • We have been the victim of a cyber-related crime and our controls may not be successful in avoiding further cyber-related crimes in the future.
  • Risks Related to our Intellectual Property
  • Our ability to protect our intellectual property and proprietary technology is uncertain.
  • There is limited market awareness of our technology, and we may not be able to establish or strengthen our brand.
  • We could become subject to patent litigation that could be costly, result in the diversion of management’s time and efforts, stop our development and commercialization measures or require us to pay damages.
  • We may be subject to damages resulting from claims that we, or our employees, have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • Risks Related to our Legal and Regulatory Environment
  • Our products and operations are subject to extensive governmental regulation, and any adverse regulatory action may materially adversely affect our financial condition and business operations.
  • A recall of our products, or the discovery of serious safety issues with our products, could have a significant negative impact on us.
  • We are subject to additional federal, state and foreign laws and regulations relating to our healthcare business; our failure to comply with those laws could have an adverse impact on our business.
  • We may be liable if the FDA or another regulatory agency concludes that we have engaged in the off-label promotion of our products.
  • Legislative or regulatory healthcare reforms may have a material adverse effect on our business, financial condition, results or operations and cash flows.
  • Risks Related to our Common Stock
  • The price of our Common Stock might fluctuate.
  • If we fail to comply with the continued listing standards of the Nasdaq Capital Market, our Common Stock could be delisted. If it is delisted, our Common Stock and the liquidity of our Common Stock would be impacted.
  • Any failure to maintain an effective system of internal controls over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could result in material misstatements of our financial statements or cause us to fail to meet our reporting obligations or fail to prevent fraud in which case, our stockholders could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our stock.
  • We intend to issue more shares to raise capital, which will result in substantial dilution.
  • Anti-takeover provisions in the Company’s certificate of incorporation and bylaws may prevent or frustrate attempts by stockholders to change the Board or current management and could make a third-party acquisition of the Company difficult.
  • Our management has identified certain internal control deficiencies, which management believes constitute a material weakness. Our failure to establish and maintain an effective system of internal controls could result in material misstatements of our financial statements or cause us to fail to meet our reporting obligations or fail to prevent fraud in which case, our stockholders could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our common stock.
  • We are a smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our Common Stock less attractive to investors.
  • We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.
  • If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
  • Our Common Stock has been, and may in the future be subject to the “penny stock” rules of the SEC, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.
  • General Risk Factors
  • Adverse global economic conditions could have a negative effect on our business, results of operations and financial condition and liquidity.
  • Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition and cash flows.
  • We may seek to grow our business through acquisitions of complementary products or technologies, and the failure to complete acquisitions, or the failure to integrate them with our existing business, could harm our business, financial condition and operating results.
  • Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
  • Prolonged negative economic conditions could adversely affect us, our customers and third-party partners, manufactures or suppliers, if any, which could harm our financial condition.
  • We have incurred, and may continue to incur increased costs and demands upon management as a result of being a public company.

Legal proceedings

From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
    SEC EDGAROther events
  38. 38
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58